Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Evolus Inc
EOLS | US
4.68
USD0.04
0.86%
EOLS | US
About Evolus Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
23/03/2026
Close
4.68
Open
4.65
High
4.76
Low
4.52
Evolus Inc. a performance beauty company provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus Inc. was incorporated in 2012 and is headquartered in Newport Beach California.
View LessEOLS | US
Risk
134.5
Sharpe
-0.98
Luna's Score
36/100
Recommendation
Sell
Luna says (EOLS | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
52.2%1 month
134.5%3 months
90.6%6 months
72.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
111.11
Price to book
54.29
Debt to equity
6.56
Debt to assets
0.54
Ent. to EBITDA
-21.50
Ent. to rev.
4.56
PEG
-
Other Fundamentals
EBITDA
-24.64M
MarketCap
295.28M
MarketCap(USD)
295.28M
Div. yield
-
Op. margin
-9.11
Erngs. growth
-
Rev. growth
35.60
Ret. on equity
-861.68
Short ratio
7.60
Short perc.
7.84
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.15
Range1M
2.15
Range3M
3.16
Volumes: Market Activity
Rel. volume
0.83
Price X volume
6.20M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -21.50 | - | Cheaper |
| Ent. to Revenue | 4.56 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 54.29 | 13.15 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 90.55 | - | Riskier |
| Debt to Equity | 6.56 | -1.88 | Expensive |
| Debt to Assets | 0.54 | 0.48 | Par |
| Market Cap | 295.28M | - | Emerging |
